^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    finotonlimab (SCT-I10A)

    i
    Other names: SCT-I10A, SCT-I10, SCT I10A, SCTI10A
    Associations

    News

    Trials
    Company:
    Sinocelltech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=188, Terminated, Sinocelltech Ltd. | N=360 --> 188 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Feb 2023; Strategy adjustments, independent of the safety and efficacy of the trial medication
    Enrollment change • Trial termination • Trial primary completion date • Metastases
    |
    EGFR mutation
    |
    docetaxel • finotonlimab (SCT-I10A)
    11ms
    SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=405, Active, not recruiting, Sinocelltech Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    sorafenib • Ambezhu (bevacizumab biosimilar) • finotonlimab (SCT-I10A)
    12ms
    Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer. (PubMed, Cancer Biol Med)
    SCT200 combined with SCT-I10A demonstrated promising efficacy in previously treated RAS/BRAF wt mCRC patients with an acceptable safety profile. Further head-to-head studies with larger sample sizes are needed to validate whether the efficacy and safety of combined anti-EGFR and anti-PD-1 therapy are superior to anti-EGFR monotherapy in the third-line setting. (Registration No. NCT04229537).
    P1 data • Journal • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    SCT200 • finotonlimab (SCT-I10A)
    2years
    SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=120, Recruiting, Sinocelltech Ltd.
    New P1 trial • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    paclitaxel • docetaxel • SCT200 • finotonlimab (SCT-I10A)
    almost5years
    SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=330, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    finotonlimab (SCT-I10A)
    5years
    Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=103, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    finotonlimab (SCT-I10A)